Stocks · News reference
Filed: 2026-09-09 AccNo: 0001193125-26-385881 Size: 142 KB Item 8.01: Other Events
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (Nasdaq: KURA, "Kura") plan to outline the development strategy for KO-7246, Caspian’s selective, oral menin inhibitor designed for diabetes
Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.
Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura"))) today announced comprehensive preclinical data supporting KO-7246 as a potential best-in-class menin inhibitor for